Noel S. Weiss
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Noel S. Weiss has a total of 194 co-authors. Here are the top co-authors by number of shared publications:
Thomas D. Koepsell
30 shared publications- Theodore Robert Levin
Kaiser Permanente Division of Research, Pleasanton, California, USA
26 shared publications - Douglas A. Corley
Division of Research, Kaiser Permanente Northern California, Oakland, California, USA
25 shared publications - Amanda I. Phipps
Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington
24 shared publications - Aruna Kamineni
Kaiser Permanente Washington Health Research Institute , Seattle, WA
24 shared publications - Beverly B. Green
Kaiser Permanente Washington Health Research Institute, Seattle, Washington
24 shared publications
Latest Publications
- Open Access
- 6 September 2026
- Published by Springer Nature in Abdominal Radiology
- p. 1-10
Radiology considerations for the PREMIUM study: a multicenter randomized controlled trial of abbreviated MRI versus ultrasound for liver cancer screening in cirrhosis
This paper describes the rationale and radiology considerations in the implementation of the Preventing Liver Cancer Mortality through Imaging with Ultrasound versus MRI (PREMIUM) study. PREMIUM is a multicenter, randomized controlled trial sponsored by the Department of Veterans Affairs comparing dynamic contrast-enhanced (DCE) abbreviated MRI (aMRI) plus serum AFP versus ultrasound (US) plus serum AFP for hepatocellular carcinoma (HCC) screening in patients with cirrhosis. PREMIUM aims to randomize 4,700 participants across over 47 Veterans Affairs Medical Centers to semiannual surveillance for up to eight years, with HCC-related mortality as the primary endpoint. To date, 35 sites have been activated with 1,085 patients randomized. To ensure uniform implementation and reporting of per-protocol screening, the PREMIUM Radiology Workgroup developed standardized imaging protocols, structured LI-RADS–based reporting templates, and a centralized training program for radiologists and technologists. They also perform ongoing quality control on both scans and reports. The aMRI protocols utilize multiphasic post-contrast imaging to allow LI-RADS scoring. A non-contrast-enhanced aMRI protocol is available for participants who develop renal impairment or contrast allergy during the study. US protocols conform to US LI-RADS standards. Structured reporting promotes consistency in documentation of findings, visualization scores, and follow-up recommendations. A centralized Image Repository was established, incorporating advanced de-identification methods to remove metadata and pixel-embedded protected health information from imaging files. More than 20,000 curated liver MRI and US exams are anticipated, supporting both trial outcomes and future radiomics and artificial intelligence research. PREMIUM aims to determine whether screening for HCC with a DCE aMRI protocol reduces HCC-related mortality and also facilitates ancillary studies utilizing the Image Repository.
- 6 September 2026
- Published by Springer Nature in Abdominal Radiology
- p. 1-10
Open AccessRadiology considerations for the PREMIUM study: a multicenter randomized controlled trial of abbreviated MRI versus ultrasound for liver cancer screening in cirrhosis
This paper describes the rationale and radiology considerations in the implementation of the Preventing Liver Cancer Mortality through Imaging with Ultrasound versus MRI (PREMIUM) study. PREMIUM is a multicenter, randomized controlled trial sponsored by the Department of Veterans Affairs comparing dynamic contrast-enhanced (DCE) abbreviated MRI (aMRI) plus serum AFP versus ultrasound (US) plus serum AFP for hepatocellular carcinoma (HCC) screening in patients with cirrhosis. PREMIUM aims to randomize 4,700 participants across over 47 Veterans Affairs Medical Centers to semiannual surveillance for up to eight years, with HCC-related mortality as the primary endpoint. To date, 35 sites have been activated with 1,085 patients randomized. To ensure uniform implementation and reporting of per-protocol screening, the PREMIUM Radiology Workgroup developed standardized imaging protocols, structured LI-RADS–based reporting templates, and a centralized training program for radiologists and technologists. They also perform ongoing quality control on both scans and reports. The aMRI protocols utilize multiphasic post-contrast imaging to allow LI-RADS scoring. A non-contrast-enhanced aMRI protocol is available for participants who develop renal impairment or contrast allergy during the study. US protocols conform to US LI-RADS standards. Structured reporting promotes consistency in documentation of findings, visualization scores, and follow-up recommendations. A centralized Image Repository was established, incorporating advanced de-identification methods to remove metadata and pixel-embedded protected health information from imaging files. More than 20,000 curated liver MRI and US exams are anticipated, supporting both trial outcomes and future radiomics and artificial intelligence research. PREMIUM aims to determine whether screening for HCC with a DCE aMRI protocol reduces HCC-related mortality and also facilitates ancillary studies utilizing the Image Repository.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Risk of colorectal cancer and colorectal cancer mortality beginning one year after a negative fecal occult blood test, among screen-eligible 76-85-year-olds
Figure S-1 illustrates selection of eligible study population from PRECISE cohort.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Risk of colorectal cancer and colorectal cancer mortality beginning one year after a negative fecal occult blood test, among screen-eligible 76-85-year-olds
Figure S-1 illustrates selection of eligible study population from PRECISE cohort.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Risk of colorectal cancer and colorectal cancer mortality beginning one year after a negative fecal occult blood test, among screen-eligible 76-85-year-olds
Table S-2 displays cumulative risk of death from other causes (competing risk to CRC mortality estimates#), stratified by patient characteristics at index date.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Risk of colorectal cancer and colorectal cancer mortality beginning one year after a negative fecal occult blood test, among screen-eligible 76-85-year-olds
Table S-2 displays cumulative risk of death from other causes (competing risk to CRC mortality estimates#), stratified by patient characteristics at index date.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Risk of colorectal cancer and colorectal cancer mortality beginning one year after a negative fecal occult blood test, among screen-eligible 76-85-year-olds
Table S-1 shows characteristics of screen-eligible patients aged 76-85 years at index date, stratified by healthcare system.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Risk of colorectal cancer and colorectal cancer mortality beginning one year after a negative fecal occult blood test, among screen-eligible 76-85-year-olds
Table S-1 shows characteristics of screen-eligible patients aged 76-85 years at index date, stratified by healthcare system.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Risk of colorectal cancer and colorectal cancer mortality beginning one year after a negative fecal occult blood test, among screen-eligible 76-85-year-olds
Background: Colorectal cancer (CRC) screening is universally recommended for adults ages 45-75 years. Noninvasive fecal occult blood tests are effective screening tests recommended by guidelines. However, empirical evidence to inform older adults’ decisions about whether to continue screening is sparse, especially for individuals with prior screening. Methods: This study used a retrospective cohort of older adults at three Kaiser Permanente integrated healthcare systems (Northern California, Southern California, Washington) and Parkland Health (Dallas, Texas). Beginning one year following a negative stool-based screening test, cumulative risks of CRC incidence, CRC mortality (accounting for deaths from other causes), and non-CRC mortality were estimated. Results: Cumulative incidence of CRC in screen-eligible adults aged 76-85 with a negative fecal occult blood test one year ago (N=118,269) was 0.23% (95% confidence interval [CI]: 0.20-0.26%) after two years and 1.21% (95% CI:1.13-1.30%) after eight years. Cumulative CRC mortality was 0.03% (95% CI: 0.02-0.04%) after two years and 0.33% (95% CI: 0.28-0.39%) after eight years. Cumulative risk of death from non-CRC causes was 4.81% (95% CI: 4.68-4.96%) after two years and 28.40% (95% CI: 27.95-28.85%) after eight years. Conclusion: Among 76-85 year-olds with a recent negative stool-based test, cumulative CRC incidence and mortality estimates were low, especially within two years; death from other causes was over 100 times more likely than death from CRC. Impact: These findings of low absolute CRC risk, and comparatively higher risk of death from other causes, can inform decision-making regarding whether and when to continue CRC screening beyond age 75 among screen-eligible adults.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Risk of colorectal cancer and colorectal cancer mortality beginning one year after a negative fecal occult blood test, among screen-eligible 76-85-year-olds
Background: Colorectal cancer (CRC) screening is universally recommended for adults ages 45-75 years. Noninvasive fecal occult blood tests are effective screening tests recommended by guidelines. However, empirical evidence to inform older adults’ decisions about whether to continue screening is sparse, especially for individuals with prior screening. Methods: This study used a retrospective cohort of older adults at three Kaiser Permanente integrated healthcare systems (Northern California, Southern California, Washington) and Parkland Health (Dallas, Texas). Beginning one year following a negative stool-based screening test, cumulative risks of CRC incidence, CRC mortality (accounting for deaths from other causes), and non-CRC mortality were estimated. Results: Cumulative incidence of CRC in screen-eligible adults aged 76-85 with a negative fecal occult blood test one year ago (N=118,269) was 0.23% (95% confidence interval [CI]: 0.20-0.26%) after two years and 1.21% (95% CI:1.13-1.30%) after eight years. Cumulative CRC mortality was 0.03% (95% CI: 0.02-0.04%) after two years and 0.33% (95% CI: 0.28-0.39%) after eight years. Cumulative risk of death from non-CRC causes was 4.81% (95% CI: 4.68-4.96%) after two years and 28.40% (95% CI: 27.95-28.85%) after eight years. Conclusion: Among 76-85 year-olds with a recent negative stool-based test, cumulative CRC incidence and mortality estimates were low, especially within two years; death from other causes was over 100 times more likely than death from CRC. Impact: These findings of low absolute CRC risk, and comparatively higher risk of death from other causes, can inform decision-making regarding whether and when to continue CRC screening beyond age 75 among screen-eligible adults.
- 1 April 2026
- Published by Springer Nature in European Journal of Epidemiology
- Vol. 41 (4) , 393-394
The analysis of cancer screening trials in which the outcome is the incidence of late-stage disease
The National Health Service-Galleri randomized trial seeks to determine the extent to which a blood-based multi-cancer screening test can lead to a reduced incidence of a variety of cancers that are at a late stage as of the time of initial diagnosis. In February 2026, the investigators of this trial issued a news release indicating that after several years of follow-up, for a group of 12 pre-specified forms of cancer there was a lower incidence of stage IV cancer among patients in the intervention arm of the trial than in the control arm. The release stated that a group of participants whose stage IV cancer could not have been influenced by the screening – those with stage IV disease already present as of the initial screening exam – had been excluded from this analysis. We argue that while it is appropriate to restrict such an analysis to persons without prevalent stage IV cancer at the start of the trial, a valid result will be obtained only after accounting for the counterparts of these cases that are present in the trial’s control arm. We describe how this can be accomplished, and the assumptions needed for such a strategy to succeed.
- 1 April 2026
- Published by Springer Nature in European Journal of Epidemiology
- Vol. 41 (4) , 393-394
The analysis of cancer screening trials in which the outcome is the incidence of late-stage disease
The National Health Service-Galleri randomized trial seeks to determine the extent to which a blood-based multi-cancer screening test can lead to a reduced incidence of a variety of cancers that are at a late stage as of the time of initial diagnosis. In February 2026, the investigators of this trial issued a news release indicating that after several years of follow-up, for a group of 12 pre-specified forms of cancer there was a lower incidence of stage IV cancer among patients in the intervention arm of the trial than in the control arm. The release stated that a group of participants whose stage IV cancer could not have been influenced by the screening – those with stage IV disease already present as of the initial screening exam – had been excluded from this analysis. We argue that while it is appropriate to restrict such an analysis to persons without prevalent stage IV cancer at the start of the trial, a valid result will be obtained only after accounting for the counterparts of these cases that are present in the trial’s control arm. We describe how this can be accomplished, and the assumptions needed for such a strategy to succeed.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Risk of Colorectal Cancer and Colorectal Cancer Mortality Beginning One Year after a Negative Fecal Occult Blood Test, among Screen-Eligible 76- to 85-Year-Olds
Table S-2 displays cumulative risk of death from other causes (competing risk to CRC mortality estimates#), stratified by patient characteristics at index date.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Risk of Colorectal Cancer and Colorectal Cancer Mortality Beginning One Year after a Negative Fecal Occult Blood Test, among Screen-Eligible 76- to 85-Year-Olds
Table S-2 displays cumulative risk of death from other causes (competing risk to CRC mortality estimates#), stratified by patient characteristics at index date.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S-4 from Risk of Colorectal Cancer and Colorectal Cancer Mortality Beginning Ten Years after a Negative Colonoscopy, among Screen-Eligible Adults 76 to 85 Years Old
Table S-4 shows cumulative mortality estimates from non-CRC causes (competing events), corresponding to mortality estimates (Table 3)
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S-4 from Risk of Colorectal Cancer and Colorectal Cancer Mortality Beginning Ten Years after a Negative Colonoscopy, among Screen-Eligible Adults 76 to 85 Years Old
Table S-4 shows cumulative mortality estimates from non-CRC causes (competing events), corresponding to mortality estimates (Table 3)
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Risk of Colorectal Cancer and Colorectal Cancer Mortality Beginning One Year after a Negative Fecal Occult Blood Test, among Screen-Eligible 76- to 85-Year-Olds
Figure S-1 illustrates selection of eligible study population from PRECISE cohort.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Risk of Colorectal Cancer and Colorectal Cancer Mortality Beginning One Year after a Negative Fecal Occult Blood Test, among Screen-Eligible 76- to 85-Year-Olds
Figure S-1 illustrates selection of eligible study population from PRECISE cohort.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S-3 from Risk of Colorectal Cancer and Colorectal Cancer Mortality Beginning Ten Years after a Negative Colonoscopy, among Screen-Eligible Adults 76 to 85 Years Old
Table S-3 shows cumulative CRC mortality estimates, stratified by additional covariates (sensitivity analysis; Charlson Comorbidity Index scores by age group; comorbid conditions).
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S-3 from Risk of Colorectal Cancer and Colorectal Cancer Mortality Beginning Ten Years after a Negative Colonoscopy, among Screen-Eligible Adults 76 to 85 Years Old
Table S-3 shows cumulative CRC mortality estimates, stratified by additional covariates (sensitivity analysis; Charlson Comorbidity Index scores by age group; comorbid conditions).